Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Switzerland-based BioCopy AG has collaborated with Immatics N.V. (NASDAQ:IMTX) to characterize T cell receptors (TCRs).
- T cell receptors and their interactions with peptide-HLA complexes (human leukocyte antigen) play a crucial role for the human immune system in recognition of tumors, among other things.
- BioCopy's technology enables high-throughput screening of T cell receptors for binding to a wide variety of peptide-HLA complexes, thus contributing a safety screening for novel TCR-based cancer cell therapies.
- This collaboration aims to enable the characterization of more than 5,000 different TCR-peptide-HLA interactions simultaneously to accelerate the development of T-cell-based cancer therapies by facilitating large pre-clinical safety screenings.
- Price Action: IMTX shares are down 0.34% at $11.75 on the last check Wednesday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!